Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 9

1.

Human breast cancer cells harboring a gatekeeper T798M mutation in HER2 overexpress EGFR ligands and are sensitive to dual inhibition of EGFR and HER2.

Rexer BN, Ghosh R, Narasanna A, Estrada MV, Chakrabarty A, Song Y, Engelman JA, Arteaga CL.

Clin Cancer Res. 2013 Oct 1;19(19):5390-401. doi: 10.1158/1078-0432.CCR-13-1038. Epub 2013 Aug 15.

2.

Trastuzumab has preferential activity against breast cancers driven by HER2 homodimers.

Ghosh R, Narasanna A, Wang SE, Liu S, Chakrabarty A, Balko JM, González-Angulo AM, Mills GB, Penuel E, Winslow J, Sperinde J, Dua R, Pidaparthi S, Mukherjee A, Leitzel K, Kostler WJ, Lipton A, Bates M, Arteaga CL.

Cancer Res. 2011 Mar 1;71(5):1871-82. doi: 10.1158/0008-5472.CAN-10-1872. Epub 2011 Feb 15.

3.

Loss of phosphatase and tensin homolog or phosphoinositol-3 kinase activation and response to trastuzumab or lapatinib in human epidermal growth factor receptor 2-overexpressing locally advanced breast cancers.

Dave B, Migliaccio I, Gutierrez MC, Wu MF, Chamness GC, Wong H, Narasanna A, Chakrabarty A, Hilsenbeck SG, Huang J, Rimawi M, Schiff R, Arteaga C, Osborne CK, Chang JC.

J Clin Oncol. 2011 Jan 10;29(2):166-73. doi: 10.1200/JCO.2009.27.7814. Epub 2010 Dec 6.

4.

Inhibition of mammalian target of rapamycin is required for optimal antitumor effect of HER2 inhibitors against HER2-overexpressing cancer cells.

Miller TW, Forbes JT, Shah C, Wyatt SK, Manning HC, Olivares MG, Sanchez V, Dugger TC, de Matos Granja N, Narasanna A, Cook RS, Kennedy JP, Lindsley CW, Arteaga CL.

Clin Cancer Res. 2009 Dec 1;15(23):7266-76. doi: 10.1158/1078-0432.CCR-09-1665. Epub 2009 Nov 24.

5.

Microenvironmental independence associated with tumor progression.

Anderson AR, Hassanein M, Branch KM, Lu J, Lobdell NA, Maier J, Basanta D, Weidow B, Narasanna A, Arteaga CL, Reynolds AB, Quaranta V, Estrada L, Weaver AM.

Cancer Res. 2009 Nov 15;69(22):8797-806. doi: 10.1158/0008-5472.CAN-09-0437. Epub 2009 Nov 3.

6.

Loss of Phosphatase and Tensin homologue deleted on chromosome 10 engages ErbB3 and insulin-like growth factor-I receptor signaling to promote antiestrogen resistance in breast cancer.

Miller TW, Pérez-Torres M, Narasanna A, Guix M, Stål O, Pérez-Tenorio G, Gonzalez-Angulo AM, Hennessy BT, Mills GB, Kennedy JP, Lindsley CW, Arteaga CL.

Cancer Res. 2009 May 15;69(10):4192-201. doi: 10.1158/0008-5472.CAN-09-0042. Epub 2009 May 12.

7.

Convergence of p53 and transforming growth factor beta (TGFbeta) signaling on activating expression of the tumor suppressor gene maspin in mammary epithelial cells.

Wang SE, Narasanna A, Whitell CW, Wu FY, Friedman DB, Arteaga CL.

J Biol Chem. 2007 Feb 23;282(8):5661-9. Epub 2007 Jan 4.

8.

HER2 kinase domain mutation results in constitutive phosphorylation and activation of HER2 and EGFR and resistance to EGFR tyrosine kinase inhibitors.

Wang SE, Narasanna A, Perez-Torres M, Xiang B, Wu FY, Yang S, Carpenter G, Gazdar AF, Muthuswamy SK, Arteaga CL.

Cancer Cell. 2006 Jul;10(1):25-38.

9.

alpha-Synuclein produces a long-lasting increase in neurotransmitter release.

Liu S, Ninan I, Antonova I, Battaglia F, Trinchese F, Narasanna A, Kolodilov N, Dauer W, Hawkins RD, Arancio O.

EMBO J. 2004 Nov 10;23(22):4506-16. Epub 2004 Oct 28.

Supplemental Content

Loading ...
Support Center